IBD Evidence

Article

Anxiety and depression in IBD: what the research shows

Inflammatory bowel disease is measured in the gut: calprotectin, endoscopy, biopsies. The way it is lived includes a great deal that those measurements miss, and anxiety and depression are among the best-studied parts of that gap.

Оновлено 2 хв читання 28 цитування

Street view of the station pharmacy building in Bautzen, Germany
Fiver, der Hellseher · CC BY-SA 4.0 · Wikimedia Commons

How common it is

A systematic review and meta-analysis in The Lancet Gastroenterology & Hepatology set out to estimate the prevalence of anxiety and depression symptoms in people with inflammatory bowel disease [6]. A pooled estimate like this describes a population, not an individual, but the fact that it needed a meta-analysis of its own shows how established the question has become.

Quality of life moves with the disease

A systematic review and meta-analyses of quality of life in IBD examined how the condition affects day-to-day wellbeing across studies [12]. A separate systematic review asked how people with IBD cope with the disease [14], an important complement because coping is something a person can work on, unlike the course of the disease itself.

One stressor comes up repeatedly in patients' own accounts: unpredictability. Not knowing when the next flare will come, or where the nearest toilet is, can weigh on someone even when their symptoms are currently controlled.

Treatment goals now include how you feel

STRIDE-II, the international consensus on treatment targets for IBD from the International Organization for the Study of IBD, sets the goals for "treat-to-target" care [7]. Treat-to-target means setting measurable goals and adjusting treatment until they are met, rather than accepting partial control.

Psychological care has its own guidance too. The Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU), together with the patients' association ACCU, published recommendations on managing psychological problems in people with IBD [11]. A joint clinician and patient recommendation is a clear signal that this is part of care, not an optional extra.

What to bring up, and with whom

If you notice…It is worth saying to…
Persistent low mood or loss of interestYour GP or IBD team; ask whether psychological support is part of the service
Anxiety centred on flares, toilets or travelYour IBD nurse; this is a commonly reported stressor
Fatigue that makes everything harderYour IBD team; see this site's living with IBD page
Symptoms that feel out of step with your test resultsYour gastroenterologist; both sides of the picture count

A worked example

Someone newly diagnosed with Crohn's disease has well-controlled symptoms but spends a lot of energy planning around the possibility of a flare. Because unpredictability is a recognised stressor in coping research, and psychological care has dedicated guidance in IBD, it is reasonable to raise this with the care team directly rather than wait for it to become severe.

Common questions

Is depression in IBD caused by the disease or by living with a chronic illness?
The studies here do not separate the two, and both are plausible contributors.
Will controlling the inflammation improve my mood?
Disease activity and quality of life are closely linked, but the research cited here does not show that improving one guarantees improvement in the other.
Should I be screened?
Some national guidance recommends that psychological problems be actively managed as part of IBD care. Ask your team what their practice is.
Where can I get help urgently?
If you are in crisis or thinking about harming yourself, contact emergency services or a crisis line in your country now.
Working laboratory bench set up for formulation chemistry
Cjp24 · CC BY-SA 3.0 · Wikimedia Commons
The evidence behind this page A stacked bar showing the composition of the 28 publications cited on this page by study type. 15742meta-analysis (15)randomised trial (7)review (4)other (2)
28 publications, 2012–2026. That is a mix with both trials and syntheses in it, which is the position from which a claim about cause is reasonable. Source: this page’s own citation list, below.

Посилання

Кожне посилання нижче веде до оригінального рецензованого запису на PubMed або через DOI. Нічого з цього не є заміною медичної поради.

  1. Evaluating the causal connections between sleep duration and disease prevalence: A comprehensive systematic review and meta-analysis of Mendelian randomization studies Wang Z, Yao L, Tu M · Medicine · 2026 · Meta-analysis DOIPubMed 41517697Full text
  2. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition position paper on the therapeutic drug monitoring in pediatric inflammatory bowel disease Felipez LM, Ali S, de Zoeten EF, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40692184Full text
  3. Risk factors for herpes zoster infections: a systematic review and meta-analysis unveiling common trends and heterogeneity patterns Steinmann M, Lampe D, Grosser J, et al. · Infection · 2024 · Meta-analysis DOIPubMed 38236326Full text
  4. Vitamin D for the treatment of inflammatory bowel disease Wallace C, Gordon M, Sinopoulou V, et al. · The Cochrane database of systematic reviews · 2023 · Systematic review DOIPubMed 37781953Full text
  5. Nutrition, Nutritional Status, Micronutrients Deficiency, and Disease Course of Inflammatory Bowel Disease Valvano M, Capannolo A, Cesaro N, et al. · Nutrients · 2023 · Systematic review DOIPubMed 37686856Full text
  6. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis Barberio B, Zamani M, Black CJ, et al. · The lancet. Gastroenterology & hepatology · 2021 · Meta-analysis DOIPubMed 33721557
  7. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD Turner D, Ricciuto A, Lewis A, et al. · Gastroenterology · 2021 · Systematic review DOIPubMed 33359090
  8. ACG Clinical Guideline: Management of Irritable Bowel Syndrome Lacy BE, Pimentel M, Brenner DM, et al. · The American journal of gastroenterology · 2021 · Clinical guideline DOIPubMed 33315591
  9. Pediatric Psoriasis Comorbidities Kittler NW, Cordoro KM · Skin therapy letter · 2020 · Clinical guideline PubMed 33196156
  10. Telemedicine and Mobile Health Technology Are Effective in the Management of Digestive Diseases: A Systematic Review Helsel BC, Williams JE, Lawson K, et al. · Digestive diseases and sciences · 2018 · Systematic review DOIPubMed 29663265
  11. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patients Barreiro-de Acosta M, Marín-Jiménez I, Panadero A, et al. · Gastroenterologia y hepatologia · 2018 · Systematic review DOIPubMed 29275001
  12. Quality of Life in Inflammatory Bowel Disease: A Systematic Review and Meta-analyses-Part I Knowles SR, Graff LA, Wilding H, et al. · Inflammatory bowel diseases · 2018 · Meta-analysis DOIPubMed 29562277
  13. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target Peyrin-Biroulet L, Sandborn W, Sands BE, et al. · The American journal of gastroenterology · 2015 · Systematic review DOIPubMed 26303131
  14. How IBD patients cope with IBD: a systematic review McCombie AM, Mulder RT, Gearry RB · Journal of Crohn's & colitis · 2013 · Systematic review DOIPubMed 22718016
  15. Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis Lee TW, Kolber MR, Fedorak RN, et al. · Journal of Crohn's & colitis · 2012 · Meta-analysis DOIPubMed 22405161
  16. Health-related quality of life in youth with chronic gastrointestinal disease following a biofeedback enhanced cognitive behavioral therapy intervention: A randomized controlled trial Younginer ST, Westbrook A, Buzenski J, et al. · Journal of pediatric gastroenterology and nutrition · 2026 · Randomised controlled trial DOIPubMed 41486461Full text
  17. Feasibility, Acceptability, and Preliminary Effects of a Nurse-Delivered Self-Management Program for Individuals with Inflammatory Bowel Disease: A Pilot Randomized Controlled Trial Kamp K, Yoo L, Kale T, et al. · Digestive diseases and sciences · 2026 · Randomised controlled trial DOIPubMed 42470576Full text
  18. Digital self-management programme for pain, fatigue and faecal incontinence in inflammatory bowel disease: cost-effectiveness analysis of the IBD-BOOST randomised controlled trial Roukas C, Miller L, Büttner FC, et al. · BMJ open gastroenterology · 2026 · Randomised controlled trial DOIPubMed 42386349Full text
  19. Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Programme Danese S, Dignass A, Matsuoka K, et al. · Journal of Crohn's & colitis · 2024 · Randomised controlled trial DOIPubMed 38869019Full text
  20. Acceptance and Commitment Therapy for Adults Living With Inflammatory Bowel Disease and Distress: A Randomized Controlled Trial Naude C, Skvarc D, Maunick B, et al. · The American journal of gastroenterology · 2024 · Randomised controlled trial DOIPubMed 39162706Full text
  21. Effect of 5-Hydroxytryptophan on Fatigue in Quiescent Inflammatory Bowel Disease: A Randomized Controlled Trial Truyens M, Lobatón T, Ferrante M, et al. · Gastroenterology · 2022 · Randomised controlled trial DOIPubMed 35940251
  22. Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial Cox SR, Lindsay JO, Fromentin S, et al. · Gastroenterology · 2020 · Randomised controlled trial DOIPubMed 31586453
  23. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life Nguyen TV, Damiani G, Orenstein LAV, et al. · Journal of the European Academy of Dermatology and Venereology : JEADV · 2021 · Review DOIPubMed 32460374
  24. Iron Deficiency Anemia in Inflammatory Bowel Diseases-A Narrative Review Mahadea D, Adamczewska E, Ratajczak AE, et al. · Nutrients · 2021 · Review DOIPubMed 34836263Full text
  25. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities Elmets CA, Leonardi CL, Davis DMR, et al. · Journal of the American Academy of Dermatology · 2019 · Review DOIPubMed 30772097
  26. Fatigue in inflammatory bowel disease Grimstad T, Norheim KB · Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke · 2016 · Review DOIPubMed 27830906
  27. Psychological symptoms and quality of life in patients with inflammatory bowel disease in China: A multicenter study Zhang J, Liu C, An P, et al. · United European gastroenterology journal · 2024 · Journal article DOIPubMed 38315582Full text
  28. Remission in axial spondyloarthritis: Developing a consensus definition Fernández-Carballido C, Collantes-Estévez E, Gratacós J, et al. · Reumatologia clinica · 2021 · Journal article DOIPubMed 34301380

This page is not translated into this language yet and is shown in English. Translation is in progress.